



Conatus Pharmaceuticals  
Investor Relations Department  
16745 W. Bernardo Drive  
Ste 200  
San Diego, CA 92127  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: CNAT**

Last Trade:	5.04
Trade Time:	1:20 PM ET Aug 21, 2017
Change:	0.03 <span style="color: green;">↑</span> (+0.599%)
Day Range	4.95 - 5.10
52-Week Range	1.45 - 9.40
Volume	73,682

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Stock Performance



## Press Releases [\[ View all \]](#)

Aug 14, 2017

[Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis](#)

Aug 2, 2017

[Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates](#)

Jul 26, 2017

[Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results](#)

Jul 6, 2017

[Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of \\$7 Million Payment](#)

Jun 26, 2017

[FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)